ArticleInvestigational new drugs2020

Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.

Jae Yoon Jeon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.